|
WO2021068752A1
|
|
Fusion protein containing human interleukin-10 and fc fragment and medical use thereof
|
|
CN111690065A
|
|
Purification method of anti-IL-17 RA monoclonal antibody
|
|
CN110974958A
|
|
Injection preparation of anti-PD-L1 monoclonal antibody
|
|
CN110964111A
|
|
anti-PD-L1 monoclonal antibody, antigen binding fragment thereof and application thereof
|
|
CN110840830A
|
|
Injection preparation of anti-CTLA-4 monoclonal antibody
|
|
CN110655579A
|
|
Novel anti-CTLA-4 monoclonal antibody and application thereof
|
|
CN110623921A
|
|
Bispecific antibody injection preparation for resisting CD3 and CD19
|
|
CN110577603A
|
|
anti-CD 3 and anti-CD 19 bispecific antibody
|
|
US2019144541A1
|
|
Anti-PD-1 monoclonal antibody and obtaining method therefor
|
|
CN109678969A
|
|
A kind of purification process of CTLA4-Ig fusion protein
|
|
CN109394681A
|
|
A kind of ejection preparation containing Exendin-4 Fc fusion protein
|
|
CN108059680A
|
|
A kind of bispecific antibody for CD20 and CD3
|
|
CN107916276A
|
|
A kind of novel T cell immunomodulator bioactivity detection method
|
|
CN106674349A
|
|
Improved anti-VEGFR (vascular endothelial growth factor receptor)-2 monoclonal antibody
|
|
CN107698679A
|
|
Anti- PCSK9 monoclonal antibodies
|
|
CN106632681A
|
|
Anti-EGFR (epidermal growth factor receptor) and anti-CD3 (cluster of differentiation 3) bispecific antibody and application thereof
|
|
CN105078932A
|
|
Method for increasing fine particle proportion of medicinal preparation and preparation
|
|
CN104894273A
|
|
Reporter gene detection method for biological activity of T cell activation regulator
|
|
CN104946687A
|
|
Mammal dual gene highly efficient screening expression vectors and construction method thereof
|
|
CN105061597A
|
|
Anti-PD-1 monoclonal antibody and obtaining method thereof
|
